Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 8 results found. Search for [ oral Favipiravir tablets ]

Results 1 to 8 of 8
BusinessToday.In
May 4, 2021
Bajaj Healthcare Limited (BHL) has received approval from India's drug regulator, to manufacture and market 'Favijaj' in India for the treatment of COVID-19 from May 4, 2021, onwards


BusinessToday.In
November 23, 2020
The study found that patients of confirmed COVID-19 with moderate symptoms were discharged from hospital earlier than those patients that did not receive Favipiravir, with the median time to clinical cure reduced by 2.5 days compared with the control group.


BusinessToday.In
August 6, 2020
Coronavirus treatment: With the 400 mg FabiFlu, patients could undergo a more relaxed dosage. The company said that reducing pill burden has been a demand from doctors and patients alike


E Kumar Sharma
July 29, 2020
With this, close to 10 players -- Glenmark, Cipla and Dr Reddy's and others -- are either in the market or soon to launch. Currently, the drug is being sold in prices ranging between Rs 39 and Rs 75 per tablet for 200mg


BusinessToday.In
July 22, 2020
Coronavirus treatment: Patients who were administered Glenmark's FabiFlu saw 40 per cent faster achievement of clinical cure


BusinessToday.In
July 2, 2020
Opposition parties are against this decision by the BMC saying that the corporation could purchase the medicine at a much cheaper cost as at least two more Indian companies will get the licence to manufacture Favipiravir soon cutting down the cost


E Kumar Sharma
July 1, 2020
Avigan, an antiviral drug to fight influenza, is believed to be effective in treatment of COVID-19 patients


PB Jayakumar
New Delhi, June 20, 2020
Glenmark developed active pharmaceutical ingredient and formulation for FabiFlu through in-house R&D; DCGI allowed fasttrack trials with Phase III in limited patients; approval process is also under Emergency Use Authorisation


PAGES 1 OF 1